Extracorporeal photochemotherapy (ECP) is a fascinating type of immunotherapy that is capable of providing immune tolerance without immunosuppression. A clinical benefit has first been suggested in patients with chronic GVHD, and several prospective or retrospective studies reported promising results in patients with steroid refractory acute GVHD (aGVHD). 1, 2 The theoretical advantages of ECP are no increased risk of infection, no adverse events such as metabolic or organic impairment and potential preservation of the GVL effect. 2 Moreover, as its immunomodulatory effects do not rely on the destruction or inactivation of cells but rather on the generation of active immune cells, these effects can be sustained and no severe flare-up of GVHD has been reported. 1 In a recent retrospective study, Calore et al. 3 have compared the outcome of children with aGVHD depending on whether they had been treated with ECP or not. In this study, the indications for ECP were steroid resistance or dependence, or viral reactivations. The authors reported a nonsignificant rise in the survival rate of children in the ECP group compared with children who did not meet the indications for ECP. In particular, in this group of 15 patients of whom 4 had grade IV aGVHD, none died from either aGVHD or chronic GVHD.
In our center, the indications for ECP are steroid refractory or steroid-dependent aGVHD, or grade X2 aGVHD that responds to 'conventional treatment' (steroids þ CYA as first-line therapy, mycophenolate or monoclonal antibodies as second-line therapy) but has intolerable treatment-related side effects. From January 2001 to June 2008, 42 children with hematological malignancy received myeloablative-conditioned allogeneic BM transplants. In total, 17 patients had grade I aGVHD or no GVHD (group NG ¼ no GVHD). Overall, grades II-IV aGVHD occurred in 25 of 42 patients (59%) and 14 of those (34%) had either grade III or IV. All 25 patients received a combination of steroids (median 1.5 mg/kg/day, range 0.5-4) and CYA A as first-line therapy. In total, 13 responded to this treatment before 8-day steroid treatment (median 5 days) and suffered no severe side effects. Steroids were then gradually tapered and could be stopped on day 72 (range 31-143) (group SO ¼ steroids only). Overall, 12 patients received ECP as second-or third-line therapy for refractory or steroid-dependent GVHD (n ¼ 10), or for intolerable adverse effects of the immunosuppressive therapy (n ¼ 2) (ECP group). In total, five patients received ECP in combination with another treatment because of lifethreatening GVHD (two patients) or because the secondline therapy was not stopped immediately after initiation of ECP (three patients). No patients were treated with ECP because of previous viral reactivation in context with GVHD. ECP was performed using the off-line process, that is, a CMN harvest with Cobe Spectra (Caridian BCT, Bourg-la-Reine, France) followed by UVA exposure (2 J/cm 2 ) by means of a UVAMATIC illuminator (VilberLourmat, Marne-la-valle´e, France) as previously described. 4 Three sessions a week were performed for 3 weeks; after that the frequency was reduced. The characteristics of these three groups of patients (no aGVHD ¼ NG, steroids only ¼ SO group or requiring ECP ¼ ECP group) are detailed in the Table 1 .
The OS was 40.6% (CI 24-58%). In total, 8 of the 17 patients without aGVHD died (seven from relapse and one from graft failure). Overall, 7 of the 13 patients from the SO group died: two patients from multi-organ failure related to aGVHD (both had a sudden aggravation of GVHD before achieving complete resolution), one from infection and four from relapse. Of the six survivors, two developed a limited chronic GVHD. After a median followup of 28 months (range 6-76), all these six patients are alive and well. The 12 patients from the ECP group received a median of 22 sessions (range 10-56) in 3.8 months (range 0.7-9). In total, six of them exhibited a complete response to ECP, four a partial response and two no response. In responders, the improvement was perceptible before 2 weeks of ECP, whereas the maximal effect was observed after 6 to 8 weeks of treatment. In total, four patients developed chronic GVHD and it was extensive in two patients. A total of four patients died from relapse (n ¼ 1), aGVHD (n ¼ 1) or chronic GVHD (n ¼ 2). After a median follow-up of 40 months (range 3-88), eight patients are alive; two of them still suffer from mild limited chronic GVHD recurrences not requiring systemic immunosuppression. Patients treated with ECP tended to have a better 5-year OS rate compared with those who responded to steroids or had no aGVHD (57% (CI 28-82%) vs 32% (CI 13-59%) vs 31% (CI 10-64%), P ¼ 0.1, respectively). The probability of EFS is shown in Figure 1a ('event' being defined as extensive chronic GVHD or relapse). Although ECP-treated patients had a most severe organ involvement, the TRM was similar as that of patients who received only steroids (Figure 1b) . Thus the difference we observed, although non-significant, is due to the highest relapse rate in the SO group. To assess whether ECP could preserve the GVL effect, we compared the outcome of patients who responded to steroids with that of patients who responded to a second-or third-line therapy, which included ECP. Although the prevalence of limited chronic GVHD among survivors was quite similar (two of six and two of eight patients, respectively, no long-term survivor suffering from extensive cGVHD), the 5-year OS rate tended to be better in patients who had been treated with ECP (71% (CI 36-92%) vs 31% (CI 10-64%), respectively, P ¼ 0.08).
Our data must be considered very cautiously without drawing any conclusion. First, because of the design of the study (retrospective, small and heterogeneous populations, multiplicity of treatmentsy). Second, because it is not clear whether the better outcome is due to the effects of ECP or to the characteristics of GVHD itself. However, this and other studies suggest that the use of ECP could lead to the strange situation in which patients who do not respond to the consensual first-line therapy with steroids have a better outcome compared with those who do. 2, 3 The ideal treatment of aGVHD must combine a potent anti-GVH effect with no impairment of anti-infectious and anti-leukemic immunity. The apparent insolvability of this challenging equation explains why, until now, no first-line combination therapy (especially including anti-CD25 monoclonal antibodies, a recognized useful second-line therapy) has done better than steroids alone to improve the OS of patients who developed acute GVH after allogeneic BMT for malignant disease. 5 To date, ECP is known to improve aGVHD while preserving immune function. The OS rate and the low number of relapses in patients treated with ECP strongly suggest that it may preserve GVL too. Furthermore, it has been suggested that the prompt initiation of ECP treatment in patients in need of secondline therapy for aGVHD could lead to an improved response rate. 1 Taken together, all these data suggest that ECP deserve to be evaluated as part of a combination in first-line therapy of aGVHD. The need of a prospective randomized study, which concludes most of the papers talking about ECP, becomes increasingly more urgent.
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The authors declare no conflict of interest. Figure 1 Outcome of patients treated with myeloablative allogeneic BMT for hematological malignancy depending on the features of acute GVHD.
(a) EFS. Events were defined as relapse or extensive chronic GVHD. Patients without acute GVHD, patients responding to steroids without severe adverse events (steroids only group), patients treated with extracorporeal photochemotherapy (ECP) for steroid refractory or steroid-dependent acute GVHD or severe aGVHD responding to 'conventional treatment' but with intolerable treatment-related side effects (ECP group). (b) TRM. Log-rank test.
